medivation american biopharmaceutical company focused development novel therapies treat serious diseases limited treatment options medivation headquartered san francisco california beginning operations december acquisition medivation neurology final ceo david medivation collaboration astellas development enzalutamide multiple stages prostate cancer breast cancer august medivation astellas announced us food drug administration fda granted approval xtandi enzalutamide capsules treatment patients metastatic castrationresistant prostate cancer previously received docetaxel xtandi oral oncedaily androgen receptor pfizer announced would acquire company august billion completed acquisition october steve david hung founded medivation watching breast cancer patient die oncology fellowship david hung said must something march medivations stock dropped per share close oneday decline volume million response security fraud classaction lawsuit initiated izard nobel alleging medivation made false misleading statements regarding effectiveness dimebon treatment alzheimers disease revealed meet primary secondary goals phase trial patients mild moderate alzheimers counsel case bernstein liebhard lead plaintiffs initially david catoosa fund lp march case dismissed plaintiffs appealed dismissal ninth circuit court appeals ninth circuit granted oral argument held friday january march ninth circuit affirmed dismissal class action catoosa fund lp v medivation inc ninth circuit stated exception tenuous unattributed statement dr schneider relates secondhand plaintiff pled facts supporting inference actual knowledge defendants plaintiff relies heavily inference due positions defendants must known unmatched nature study inference entirely speculative rise required strong inference plaintiffs allegation least compelling opposing inference one could draw facts april company linked number potential acquirers including roche astrazeneca amgen gilead sciences possible hostile bid astrazeneca reported weigh offer billion april sanofi launched billion takeover offer rejected medivation suitors celgene genentech ultimately lost august pfizer announced would acquire company per share premium closing price august acquisition completed september medivation ceo david hung ey entrepreneur year national httpsenwikipediaorgwikimedivation